Drug intelligence / Profile preview

CMDE005

Development stage: Phase 2
Lead developer: Zhejiang Shimai Pharmaceutical
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CMDE005 is a bispecific T-cell engager (BiTE) antibody designed to target both CD3 on T cells and EGFR (epidermal growth factor receptor) on tumor cells. By binding simultaneously to CD3 and EGFR, it redirects cytotoxic T lymphocytes to attack and kill EGFR-positive tumor cells. The drug is being developed for the treatment of advanced solid tumors that express EGFR. Its mechanism involves immune-mediated targeting of cancer cells via dual engagement of the immune system and tumor antigen. The drug is administered intravenously[1][2][5].

Targets

EGFR (Epidermal growth factor receptor)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on CMDE005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMDE005.